Revvity, Inc. (RVTY) DCF Valuation
TGM's two-stage DCF values Revvity, Inc. (RVTY) between $32.97 and $65.86 depending on assumptions, with a base case of $44.60. Growth is taken from the company's own record (5-year revenue CAGR (FCF growth too volatile to use) (floored at 2%)), fading to 2.5% long-run; the discount rate (9.6%) reflects its beta.
What would today's price require?
$97.82 is justified only if free cash flow grows about +16.6% a year (fading to 2.5% long-run) at a 9.6% required return — faster than the company has actually grown.
| Scenario | FCF growth (fading to 2.5%) | Discount | Value / share |
|---|---|---|---|
| Conservative | 0.5%/yr | 10.6% | $32.97 |
| Base case | 2.0%/yr | 9.6% | $44.60 |
| Optimistic | 5.0%/yr | 8.6% | $65.86 |
| Analyst DCF (FMP) | independent reference — different model | $107.66 | |
Current Price
$97.82
Market-Implied Growth
+16.6%/yr
vs -16.7% 5Y actual
Model Scenario Range
$32.97 – $65.86
model output — not a price target
RVTY DCF Fair Value Calculator
Edit the assumptions to see how they change the estimated fair value. Opens seeded with TGM's data-driven base case for RVTY (growth from its own 5-year record, discount from its beta), so the sandbox starts where the scenarios above leave off. Illustrative model — not investment advice.
Base inputs: FCF $525.0M · 0.11B shares · net debt $2.4B
Estimated Fair Value
$43.54
-55.5% vs $97.82
Sensitivity — fair value by discount rate × terminal growth
How the estimated fair value shifts with the discount rate (WACC) and terminal growth, holding your 2.0%/yr FCF growth and 10-year horizon fixed. Green = above today's $97.82; red = below. Your current case is outlined.
| WACC ↓ / Terminal → | 1.50% | 2.00% | 2.50% | 3.00% | 3.50% |
|---|---|---|---|---|---|
| 7.6% | $59.42 | $63.76 | $68.96 | $75.28 | $83.15 |
| 8.6% | $47.86 | $50.78 | $54.17 | $58.16 | $62.94 |
| 9.6% | $39.17 | $41.21 | $43.54 | $46.22 | $49.34 |
| 10.6% | $32.38 | $33.86 | $35.53 | $37.41 | $39.55 |
| 11.6% | $26.95 | $28.05 | $29.27 | $30.64 | $32.17 |
About Revvity, Inc.
Revvity, Inc., founded in 1937 and based in Waltham, Massachusetts, is a global enterprise that develops and delivers a wide array of products, services, and solutions. The company, which changed its name from PerkinElmer, Inc. in April 2023, caters to the diagnostics, life sciences, and applied services sectors worldwide. Its Discovery & Analytical Solutions division provides advanced instrumentation, reagents, informatics, software, subscriptions, and sophisticated detection and imaging technologies. These resources are designed to enable scientists to achieve significant breakthroughs in life sciences research. This segment also offers contract research and specialized laboratory services. Furthermore, it supplies analytical tools and services for assessing environmental health, including air, water, and soil, and delivers solutions to agricultural and food producers. It also serves the industrial market with analytical instrumentation for sectors such as chemical, semiconductor, electronics, energy, lubricants, petrochemicals, and polymers. The Diagnostics segment is dedicated to early detection, offering instruments, reagents, assay platforms, and software for identifying genetic disorders in pregnant individuals and young children, alongside infectious disease testing. Its products facilitate the screening of genetic abnormalities, disorders, and diseases like Down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This division also innovates technologies that support genomic workflows, leveraging protein-coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. Revvity serves a diverse clientele, including pharmaceutical and biotechnology firms, laboratories, academic and research institutions, public health authorities, private healthcare organizations, medical professionals, and government bodies.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Prahlad R. Singh